Search This Blog

Wednesday, September 18, 2024

AstraZeneca FASENRA US OK for eosinophilic granulomatosis with polyangiitis

 New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids

https://www.businesswire.com/news/home/20240918601834/en/

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.